New chemo sequence aims to shrink pancreatic tumors before surgery
NCT ID NCT05825066
First seen Feb 01, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This study tests whether giving two different chemotherapy combinations one after the other can shrink pancreatic tumors enough to allow successful surgery. About 64 adults with borderline resectable or locally advanced pancreatic cancer will receive gemcitabine plus nab-paclitaxel followed by mFOLFIRINOX. The goal is to see if this sequence increases the chance of removing all visible cancer during surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27157, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.